155 related articles for article (PubMed ID: 31322272)
21. PRPF19 regulates p53-dependent cellular senescence by modulating alternative splicing of MDM4 mRNA.
Yano K; Takahashi RU; Shiotani B; Abe J; Shidooka T; Sudo Y; Yamamoto Y; Kan S; Sakagami H; Tahara H
J Biol Chem; 2021 Jul; 297(1):100882. PubMed ID: 34144037
[TBL] [Abstract][Full Text] [Related]
22. Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties.
Prodosmo A; Giglio S; Moretti S; Mancini F; Barbi F; Avenia N; Di Conza G; Schünemann HJ; Pistola L; Ludovini V; Sacchi A; Pontecorvi A; Puxeddu E; Moretti F
J Mol Med (Berl); 2008 May; 86(5):585-96. PubMed ID: 18335186
[TBL] [Abstract][Full Text] [Related]
23. MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway.
Mancini F; Di Conza G; Pellegrino M; Rinaldo C; Prodosmo A; Giglio S; D'Agnano I; Florenzano F; Felicioni L; Buttitta F; Marchetti A; Sacchi A; Pontecorvi A; Soddu S; Moretti F
EMBO J; 2009 Jul; 28(13):1926-39. PubMed ID: 19521340
[TBL] [Abstract][Full Text] [Related]
24. MDM4 is a rational target for treating breast cancers with mutant p53.
Miranda PJ; Buckley D; Raghu D; Pang JB; Takano EA; Vijayakumaran R; Teunisse AF; Posner A; Procter T; Herold MJ; Gamell C; Marine JC; Fox SB; Jochemsen A; Haupt S; Haupt Y
J Pathol; 2017 Apr; 241(5):661-670. PubMed ID: 28097652
[TBL] [Abstract][Full Text] [Related]
25. Stemness characteristics of fibrolamellar hepatocellular carcinoma: immunohistochemical analysis with comparisons to conventional hepatocellular carcinoma.
Zenali MJ; Tan D; Li W; Dhingra S; Brown RE
Ann Clin Lab Sci; 2010; 40(2):126-34. PubMed ID: 20421623
[TBL] [Abstract][Full Text] [Related]
26. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in liver cirrhosis and hepatocellular carcinoma.
Jablkowski M; Bocian A; Bialkowska J; Bartkowiak J
J Exp Clin Cancer Res; 2005 Mar; 24(1):117-25. PubMed ID: 15943041
[TBL] [Abstract][Full Text] [Related]
27. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
Toledo F; Wahl GM
Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
[TBL] [Abstract][Full Text] [Related]
28. [mRNA levels detected by real-time quantitative RT-PCR in chronic lymphocytic leukemia and their clinical significance].
Liu L; Fang C; Dong HJ; Wang DM; Zhu DX; Qiao C; Fan L; Miao KR; Liu P; Xu W; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1145-9. PubMed ID: 22040960
[TBL] [Abstract][Full Text] [Related]
29. Cell cycle biology of fibrolamellar hepatocellular carcinoma.
Dhingra S; Li W; Tan D; Zenali M; Zhang H; Brown RE
Int J Clin Exp Pathol; 2010 Nov; 3(8):792-7. PubMed ID: 21151393
[TBL] [Abstract][Full Text] [Related]
30. Management of fibrolamellar hepatocellular carcinoma.
Chaudhari VA; Khobragade K; Bhandare M; Shrikhande SV
Chin Clin Oncol; 2018 Oct; 7(5):51. PubMed ID: 30395718
[TBL] [Abstract][Full Text] [Related]
31. Expression and clinical significance of TAp73alpha, p53, PCNA and apoptosis in hepatocellular carcinoma.
Qin HX; Nan KJ; Yang G; Jing Z; Ruan ZP; Li CL; Xu R; Guo H; Sui CG; Wei YC
World J Gastroenterol; 2005 May; 11(18):2709-13. PubMed ID: 15884108
[TBL] [Abstract][Full Text] [Related]
32. p53 Activity Dominates That of p73 upon Mdm4 Loss in Development and Tumorigenesis.
Tashakori M; Zhang Y; Xiong S; You MJ; Lozano G
Mol Cancer Res; 2016 Jan; 14(1):56-65. PubMed ID: 26527653
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-34a modulates MDM4 expression via a target site in the open reading frame.
Mandke P; Wyatt N; Fraser J; Bates B; Berberich SJ; Markey MP
PLoS One; 2012; 7(8):e42034. PubMed ID: 22870278
[TBL] [Abstract][Full Text] [Related]
34. MDM4 overexpression contributes to synoviocyte proliferation in patients with rheumatoid arthritis.
Xu N; Wang Y; Li D; Chen G; Sun R; Zhu R; Sun S; Liu H; Yang G; Dong T
Biochem Biophys Res Commun; 2010 Oct; 401(3):417-21. PubMed ID: 20863813
[TBL] [Abstract][Full Text] [Related]
35. SIRT1 regulates oncogenesis via a mutant p53-dependent pathway in hepatocellular carcinoma.
Zhang ZY; Hong D; Nam SH; Kim JM; Paik YH; Joh JW; Kwon CH; Park JB; Choi GS; Jang KY; Park CK; Kim SJ
J Hepatol; 2015 Jan; 62(1):121-30. PubMed ID: 25131770
[TBL] [Abstract][Full Text] [Related]
36. Mdm4 loss in mice expressing a p53 hypomorph alters tumor spectrum without improving survival.
Fang M; Simeonova I; Bardot B; Lejour V; Jaber S; Bouarich-Bourimi R; Morin A; Toledo F
Oncogene; 2014 Mar; 33(10):1336-9. PubMed ID: 23474762
[TBL] [Abstract][Full Text] [Related]
37. Mitochondrial MDM4 (MDMX): an unpredicted role in the p53-mediated intrinsic apoptotic pathway.
Mancini F; Moretti F
Cell Cycle; 2009 Dec; 8(23):3854-9. PubMed ID: 19887911
[TBL] [Abstract][Full Text] [Related]
38. Puzzling over MDM4-p53 network.
Mancini F; Di Conza G; Monti O; Macchiarulo A; Pellicciari R; Pontecorvi A; Moretti F
Int J Biochem Cell Biol; 2010 Jul; 42(7):1080-3. PubMed ID: 20417304
[TBL] [Abstract][Full Text] [Related]
39. Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4.
Chandler DS; Singh RK; Caldwell LC; Bitler JL; Lozano G
Cancer Res; 2006 Oct; 66(19):9502-8. PubMed ID: 17018606
[TBL] [Abstract][Full Text] [Related]
40. miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia.
Ovcharenko D; Stölzel F; Poitz D; Fierro F; Schaich M; Neubauer A; Kelnar K; Davison T; Müller-Tidow C; Thiede C; Bornhäuser M; Ehninger G; Brown D; Illmer T
Exp Hematol; 2011 Oct; 39(10):1030-1042.e7. PubMed ID: 21784052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
